Novastan (Argatroban Monohydrate)

Argatroban directly and reversibly binds to the active site of thrombin (factor IIa), preventing thrombin from converting fibrinogen to fibrin. This inhibition stops the final step of the clotting cascade, reducing clot formation while preserving other aspects of hemostasis.

The dosing regimen for Novastan is individualized. A qualified prescriber determines the infusion rate and duration based on the patient’s clinical condition, laboratory monitoring, and therapeutic goals. No standard dose is provided here.

Safety data for Argatroban in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician.

To order Novastan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

The primary alternatives to Argatroban are other direct thrombin inhibitors such as bivalirudin and lepirudin, as well as traditional heparin. Argatroban is metabolized hepatically, offering predictable anticoagulation in patients with renal impairment, whereas bivalirudin is cleared renally. Each agent has distinct pharmacokinetic profiles and monitoring requirements.

Novastan must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If temporary temperature excursions occur, discard the product according to local regulations.

Novastan is supplied as a sterile injection solution for intravenous infusion. It is administered through a controlled IV infusion pump, with dosing adjustments guided by laboratory monitoring of activated clotting time (ACT) or other appropriate coagulation tests.

The most serious risks include severe or uncontrolled bleeding, thrombocytopenia, and rare allergic reactions such as anaphylaxis. Clinicians should monitor coagulation parameters, platelet counts, and signs of hemorrhage throughout therapy.

Novastan is contraindicated in patients with known hypersensitivity to argatroban or any component of the formulation. It should also be avoided in individuals with uncontrolled active bleeding or severe hepatic failure unless the benefits clearly outweigh the risks.